Saturday 17 October 2026
Export ACHV’s income statement to Excel — free account
Achieve Life Sciences, Inc.
ACHV Healthcare Biotechnology
In the quarter to June 2026, EPS fell 116.2%, free cash flow fell 19.0% and total debt rose 63.9%, each against the same quarter a year earlier.
6.38
0.59
−8.46%
Follow ACHV
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 726.00 | 230.00 | 20.80 | 9.20 | 4.60 | 6.55 | 2.00 | 2.44 | 3.42 | 1.84 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | 3,124.00 | 2,046.00 | 640.00 | 92.60 | 18.26 | 16.10 | 8.61 | 10.30 | 5.59 | 5.78 | |||||
| People | |||||||||||||||
| People | Employees | 17 | 13 | 13 | 14 | 13 | 16 | 20 | 22 | 25 | 28 | ||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | (2) | (14) | (13) | (16) | (15) | (33) | (42) | (30) | (40) | (55) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | (1) | (11) | (13) | (16) | (15) | (33) | (42) | (30) | (40) | (55) | |||||
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (11,625.06) | (442.00) | (72.20) | (39.80) | (5.42) | (4.08) | (4.00) | (1.50) | (1.24) | (1.25) | |||||
| Cash flow | (2,020.00) | (379.46) | (60.53) | (36.93) | (4.96) | (3.63) | (3.55) | (1.23) | (0.93) | (1.13) | |||||
| Capex | 0.00 | 0.00 | (0.21) | (0.13) | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | (2,020.00) | (379.46) | (60.73) | (37.06) | (4.96) | (3.63) | (3.55) | (1.24) | (0.93) | (1.13) | |||||
| Book value | 6,100.00 | 328.29 | 90.04 | 43.81 | 13.71 | 3.45 | 0.78 | (0.07) | 0.65 | 0.49 | |||||
| Shares, m | 0 | 0 | 0 | 0 | 3 | 8 | 11 | 20 | 32 | 44 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | 0.00 | — | — | — | — | — | — | — | — | — | ||||
| P/S | 0.01 | — | — | — | — | — | — | — | — | — | |||||
| P/B | 0.18 | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | 0.06 | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | (1.85) | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | 0 | (9) | (11) | (15) | (13) | (29) | (38) | (24) | (30) | (49) | ||||
| Capex | 0 | — | 0 | 0 | 0 | — | — | 0 | — | 0 | |||||
| Free cash flow | 0 | (9) | (11) | (15) | (13) | (29) | (38) | (24) | (30) | (49) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | (3) | 4 | 12 | 14 | 34 | 40 | 6 | (4) | 30 | 31 | ||||
| Total debt | 1 | 0 | 0 | 0 | 0 | 15 | 16 | 17 | 10 | 17 | |||||
| Net debt | 1 | (5) | (15) | (16) | (36) | (28) | (9) | 1 | (24) | (20) | |||||
| Shareholders’ equity | 1 | 8 | 16 | 18 | 37 | 28 | 8 | (1) | 21 | 22 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (3.98) | (154.51) | (87.57) | (81.64) | (48.00) | (75.51) | (109.31) | (120.85) | (137.33) | (135.90) | ||||
| ROIC | (75.23) | (172.71) | (655.87) | (590.96) | (575.45) | (159,105.77) | 0.00 | 0.00 | 0.00 | (2,109.47) | |||||
| ROE | (6.49) | (249.33) | (107.15) | (96.86) | (53.24) | (101.49) | (233.04) | (869.88) | (409.51) | (257.67) | |||||
Negative figures in brackets.
Fiscal years to Dec 2014 · latest quarter Jun 2016
Charts ten years each
Achieve Life Sciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SANA Sana Biotechnology, Inc. | $740.9M | — (loss-making) | — | — | n/m | −5.46% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| IVA Inventiva S.A. Sponsored ADR | $740.0M | — (loss-making) | — (loss-making) | −10.77% (below 0%: shrinking) | n/m | −20,989.22% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| LXRX Lexicon Pharmaceuticals, Inc. | $734.2M | — (loss-making) | — (loss-making) | −97.60% (below 0%: shrinking) | n/m | −154.09% (below 0%: shrinking) | 94.36% | (3,835.26%) | Compare |
| IMMX Immix Biopharma, Inc. | $719.6M | — (loss-making) | — | — | n/m | −116.22% (below 0%: shrinking) | — | 0.00% | Compare |
| ACHV Achieve Life Sciences, Inc. | $717.2M | — (loss-making) | — | +54.44% (above 0%: growing) | n/m | −19.01% (below 0%: shrinking) | 0.00% | 0.00% | |
| FDMT 4D Molecular Therapeutics, Inc. | $711.0M | — (loss-making) | — (loss-making) | +25,106.67% (above 0%: growing) | n/m | −61.28% (below 0%: shrinking) | 100.00% | (2,037.16%) | Compare |
| ANL Adlai Nortye Ltd. Sponsored ADR | $710.1M | — | — | — | — | +46.03% (above 0%: growing) | — | — | Compare |
| OABI OmniAb, Inc. | $687.7M | — (loss-making) | — (loss-making) | +244.24% (above 0%: growing) | n/m | +211.16% (above 0%: growing) | 95.45% | (49.47%) | Compare |
| ANNX Annexon, Inc. | $682.5M | — (loss-making) | — | — | n/m | −26.41% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $715.3M | — | — | +116.74% | — | −43.84% | 47.18% | 0.00% |
Achieve Life Sciences, Inc. (ACHV) key facts
- Achieve Life Sciences, Inc. (ACHV) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, ACHV traded at $6.38, a market capitalization of $717.2 million.
- Return on equity was −257.7% and debt-to-equity -1.11.